Entries by Max

Complete Response to Pembrolizumab in a Metastatic, Castration‑Resistant Prostate Cancer Survivor

/in /by

A remarkable case published in Annals of Internal Medicine: Clinical Cases highlights a man with metastatic, castration‑resistant prostate cancer who achieved a complete and durable response to pembrolizumab after exhausting multiple standard therapies. The patient had previously received abiraterone‑based treatment followed by chemotherapy, and then olaparib, all of which he had progressed on, leaving him […]

Phase 1/2 PARTHENON Trial: AZD4956 Targets HRD in Advanced Prostate Cancer

/in , , , /by

The PARTHENON trial tests AZD4956, an experimental oral drug that blocks SMARCA2, a protein helping cancer cells rearrange their DNA to keep growing. In tumors already “weak” at fixing DNA damage due to homologous recombination deficiency (HRD), shutting down SMARCA2 creates a double hit: cells can’t remodel chromatin or repair errors, leading to collapse. This […]

HER2 FPBMC Therapy in the AM006 Phase 1/2 Trial for Metastatic Prostate Cancer

/in , , , /by

The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]

Capivasertib + Abiraterone in CAPItello-281: Promising rPFS in PTEN-Deficient mHSPC

/in , , /by

The phase 3 trial CAPItello-281, has delivered compelling evidence that capivasertib combined with abiraterone could transform treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), a subtype affecting a substantial portion of advanced cases. In this double-blind study, 1012 patients with PTEN deficiency (defined rigorously as 90% or more viable malignant cells showing no cytoplasmic staining […]

Final PEACE-3 Trial Data: Radium-223 + Enzalutamide Extends Survival by 5.6 Months in Bone mCRPC.

/in , , /by

Radium-223 plus enzalutamide significantly boosts survival for men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, according to final results from the Phase 3 PEACE-3 trial  presented at ASCO GU 2026. In this study of 446 patients with at least two bone metastases who were asymptomatic or only mildly symptomatic, adding six infusions of […]

Phase 2 Trial of Cu-64 SAR-bisPSMA Doubles Prostate Lesion Detection

/in , , /by

64Cu-SAR-bisPSMA represents a next-generation PSMA-targeted PET imaging agent for prostate cancer, demonstrating superior lesion and patient detection in the Phase 2 Co-PSMA trial announced in February 2026. In this head-to-head study of 50 patients with biochemical recurrence (BCR) after prostatectomy (PSA 0.2-0.75 ng/mL), Cu-64 SAR-bisPSMA more than doubled mean lesions per patient at 1.26 (63 […]

Newsletter 9/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! It looks like I’ll have to start updating the clinical trials table again. I thought I could rest for a while, but apparently science waits for no one! And even this week, there are quite a few surprises. Stay […]

CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings

/in /by

Skeletal muscle index measured from regular CT scans works as a simple marker to predict outcomes and treatment response in newly diagnosed hormone-sensitive prostate cancer, based on this STAMPEDE study review. Low muscle, or sarcopenia, is common in advanced prostate cancer and gets worse with hormone therapy, but skeletal muscle index (SMI) uses psoas muscle […]

Igermetostat Plus Enzalutamide Delivers Promising rPFS in Post-Abiraterone mCRPC

/in , , , /by

Igermetostat (XNW5004), a selective EZH2 inhibitor, pairs effectively with enzalutamide in metastatic castration-resistant prostate cancer after prior novel hormone therapy, based on phase 1b/2 results. EZH2 inhibition reverses enzalutamide resistance through epigenetic changes in castration-resistant prostate cancer models. The study endpoints focused on recommended phase 2 dose, safety, and radiographic progression-free survival. ​Eighty-four patients enrolled […]